Harvard Apparatus Regenerative Tech Inc (NASDAQ:HART) shares are trading down considerably this morning after two stellars trading days for the stock on Friday and Monday. The move seems strictly based off of charts, after the stock entered an oversold territory on Monday. Shares were down slightly yesterday and the trend seems to have continued today.
Harvard Apparatus Regenerative Tech Inc’s (NASDAQ:HART) initial gains, which began with a slight gap up on Friday morning at $1.79 a share saw the trend continue with shares breaching $3.40 on Monday afternoon. Besides insider Saverio Lafrancesca purchasing 10,000 shares at $3.01 a piece on Tuesday, there has not been a whole lot of actual news for the company as of late. The stock is down 9.93% or $0.29 following the news, hitting $2.63 per share. Approximately 577,309 shares traded hands. HART shares have risen 1.04% since April 29, 2015 and are currently uptrending. It has outperformed the S&P500 by 1.24%.
The institutional sentiment increased to 0.76 in Q2 2015. It’s up 0.11, from 0.65 in 2015Q1. The ratio improved, as 8 funds sold all their Harvard Apparatus Regenerative Tech Inc shares they owned while 9 reduced their positions. 3 funds bought stakes while 10 increased their total positions. Institutions now own 2.64 million shares which is 18.87% less than the previous share count of 3.26 million in 2015Q1.
Penbrook Management Llc holds 0.17% of its total portfolio in Harvard Apparatus Regenerative Tech Inc, equating to 126,583 shares. Sio Capital Management Llc owns 232,712 shares representing 0.16% of their total US portfolio. Moreover, Granahan Investment Management Inc Ma has 0.01% of their total portfolio invested in the company, equating to 195,915 shares. The New Jersey-based Nj State Employees Deferred Compensation Plan has a total of 0.01% of their portfolio invested in the stock. A.R.T. Advisors Llc, a New York-based fund reported 21,833 shares owned.
Since September 21, 2015, the stock had 1 insider buy, and 0 sales for a total of $12,210 in net activity. Lafrancesca Saverio bought 9,500 shares worth $12,210.
Harvard Apparatus Regenerative Technology, Inc. is a clinical-stage biotechnology firm making regenerated organs for transplant. The company has a market cap of $35.87 million. The Company’s product, the HART-Trachea, is intended to be used to restore the structure and/or function of a severely damaged trachea . It currently has negative earnings. The HART-Trachea comprises the patient’s own bone marrow cells seeded on the Company’s InBreath porous plastic scaffold in its InBreath organ bioreactor.